{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05818553",
            "orgStudyIdInfo": {
                "id": "PRAX-562-221"
            },
            "organization": {
                "fullName": "Praxis Precision Medicines",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)",
            "officialTitle": "A Phase 2,Double-Blind,Randomized Clinical Trial to Explore the Safety,Tolerability,Efficacy, and Pharmacokinetics of PRAX-562 in Pediatric Participants With Developmental and Epileptic Encephalopathies Followed by Open-Label Extension(OLE)",
            "acronym": "EMBOLD",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-clinical-trial-of-prax-in-subjects-with-developmental-and-epileptic-encephalopathies-dee"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-08-02",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-06-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-06-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-03-17",
            "studyFirstSubmitQcDate": "2023-04-17",
            "studyFirstPostDateStruct": {
                "date": "2023-04-19",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-01-08",
            "lastUpdatePostDateStruct": {
                "date": "2024-01-10",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Praxis Precision Medicines",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a Phase 2, double-blind, randomized clinical trial to explore the safety, tolerability, efficacy, and pharmacokinetics of PRAX-562 in pediatric participants who have seizures associated with early-onset SCN2A-DEE and SCN8A-DEE."
        },
        "conditionsModule": {
            "conditions": [
                "SCN2A Encephalopathy",
                "SCN8A Encephalopathy"
            ],
            "keywords": [
                "Pediatric epilepsy",
                "NaV1.2 Voltage-Gated Sodium Channel",
                "SCN2A variant",
                "SCN8A variant",
                "Developmental and epileptic encephalopathy"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "Parallel group",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "maskingDescription": "Double-blind",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 20,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part A: Randomized, Double-Blind 0.5mg/kg/day PRAX-562 or PRAX-562/Placebo",
                    "type": "EXPERIMENTAL",
                    "description": "Eligible participants from each cohort will be randomized in a 1:1 ratio to either 0.5 milligrams/kilograms/day (mg/kg/day) PRAX-562 for 16 weeks (PRAX-562 arm) or 0.5 mg/kg/day PRAX-562 for 12 weeks and matching placebo for 4 weeks (PRAX-562/placebo arm) administered orally or via gastrostomy tube (G-tube).",
                    "interventionNames": [
                        "Drug: Part A: 0.5mg/kg/day PRAX-562 for 16 Weeks",
                        "Drug: Part A: 0.5mg/kg/day PRAX-562 for 12 Weeks and Matching Placebo for 4 Weeks"
                    ]
                },
                {
                    "label": "Part B: Open-Label Extension Treatment 0.5mg/kg/day PRAX-562",
                    "type": "EXPERIMENTAL",
                    "description": "Eligible participants will receive 0.5mg/kg/day administered orally or via G-tube for 48 weeks.",
                    "interventionNames": [
                        "Drug: Part B: 0.5mg/kg/day PRAX-562"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Part A: 0.5mg/kg/day PRAX-562 for 16 Weeks",
                    "description": "Once daily oral or G-tube treatment.",
                    "armGroupLabels": [
                        "Part A: Randomized, Double-Blind 0.5mg/kg/day PRAX-562 or PRAX-562/Placebo"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Part A: 0.5mg/kg/day PRAX-562 for 12 Weeks and Matching Placebo for 4 Weeks",
                    "description": "Once daily oral or G-tube treatment with PRAX-562 for 12 weeks and matching placebo for 4 weeks.",
                    "armGroupLabels": [
                        "Part A: Randomized, Double-Blind 0.5mg/kg/day PRAX-562 or PRAX-562/Placebo"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Part B: 0.5mg/kg/day PRAX-562",
                    "description": "Once daily oral or G-tube treatment.",
                    "armGroupLabels": [
                        "Part B: Open-Label Extension Treatment 0.5mg/kg/day PRAX-562"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of Treatment-Emergent Adverse Events (TAEs) [Safety and Tolerability])",
                    "description": "The number of participants with treatment-emergent adverse events will be reported by severity and preferred term.",
                    "timeFrame": "16 weeks"
                },
                {
                    "measure": "To evaluate the long-term safety and tolerability of PRAX-562 in pediatric participants with DEEs",
                    "description": "Incidence and severity of TEAEs",
                    "timeFrame": "48 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "To assess the effect of PRAX-562 on the frequency of countable motor seizures in pediatric participants with DEEs",
                    "description": "Changes from baseline in monthly (28-day) motor seizure frequency",
                    "timeFrame": "16 weeks"
                },
                {
                    "measure": "Plasma concentrations of PRAX-562",
                    "description": "Sparse pharmacokinetic (PK) sampling will be used to calculate mean concentrations at baseline, and at Weeks 2, 4, 6, 8,10, 12 and 16.",
                    "timeFrame": "16 weeks"
                },
                {
                    "measure": "Seizure Frequency (OLE Extension)",
                    "description": "Efficacy assessments (seizure diary) will be collected daily and reviewed at timepoints Day 1, Week 16, Week 32, and Week 48.",
                    "timeFrame": "48 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Has a documented rare missense variant in SCN2A with onset of seizures occurring in the first three months of life or has a documented de novo (not observed in either parent) missense variant in SCN8A with onset of seizures occurring in the first six months of life.\n* Has a seizure frequency as follows:\n\n  * At least 8 countable motor seizures in the 4 weeks immediately prior to Screening as reported by the parent/legal guardian or in the opinion of the investigator AND\n  * At least 8 countable motor seizures during the 28 day Baseline Observation Period (during which seizure frequency is recorded in a daily seizure diary).\n* Additional inclusion criteria apply and will be assessed by the study team.\n\nExclusion Criteria:\n\n* Has any clinically significant or known pathogenic or likely pathogenic genetic variant other than in SCN2A and SCN8A or a genetic variant that may explain or contribute to the participant's epilepsy and/or developmental disorder.\n* Has a documented, functionally characterized loss-of-function (LoF) missense variant or a presumed LoF variant (nonsense or frameshift variant) based on genetic testing and/or clinical evidence that prior exposure to a sodium channel blocker (SCB) medication worsened seizures.\n* Has 2 or more episodes of convulsive status epilepticus requiring hospitalization and intubation in the 6 months prior to Screening.\n* Additional exclusion criteria apply and will be assessed by the study team.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "2 Years",
            "maximumAge": "18 Years",
            "stdAges": [
                "CHILD",
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Head of Pharmacovigilance",
                    "role": "CONTACT",
                    "phone": "617-300-8460",
                    "email": "clinicaltrials@praxismedicines.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Medical Director",
                    "affiliation": "Praxis Precision Medicines",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Praxis Research Site",
                    "status": "RECRUITING",
                    "city": "Atlanta",
                    "state": "Georgia",
                    "zip": "30329",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.749,
                        "lon": -84.38798
                    }
                },
                {
                    "facility": "Praxis Research Site",
                    "status": "RECRUITING",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60611",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                },
                {
                    "facility": "Praxis Research Site",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02115",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Praxis Research Site",
                    "status": "RECRUITING",
                    "city": "Tacoma",
                    "state": "Washington",
                    "zip": "98405",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 47.25288,
                        "lon": -122.44429
                    }
                },
                {
                    "facility": "Praxis Research Site",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28034",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001927",
                    "term": "Brain Diseases"
                },
                {
                    "id": "D000004827",
                    "term": "Epilepsy"
                }
            ],
            "ancestors": [
                {
                    "id": "D000002493",
                    "term": "Central Nervous System Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7983",
                    "name": "Epilepsy",
                    "asFound": "Epileptic",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5204",
                    "name": "Brain Diseases",
                    "asFound": "Encephalopathy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5742",
                    "name": "Central Nervous System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T5151",
                    "name": "SCN8A Encephalopathy",
                    "asFound": "SCN8A Encephalopathy",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000005548",
                    "term": "Pramoxine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000779",
                    "term": "Anesthetics, Local"
                },
                {
                    "id": "D000000777",
                    "term": "Anesthetics"
                },
                {
                    "id": "D000002492",
                    "term": "Central Nervous System Depressants"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018689",
                    "term": "Sensory System Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M225635",
                    "name": "Pramoxine",
                    "asFound": "Salmon",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4107",
                    "name": "Anesthetics",
                    "relevance": "LOW"
                },
                {
                    "id": "M4109",
                    "name": "Anesthetics, Local",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}